Sorbents in Acute Renal Failure and the Systemic Inflammatory Response SyndromeWinchester J.F. · Kellum J.A. · Ronco C. · Brady J.A. · Quartararo P.J. · Salsberg J.A. · Levin N.W.
aRenalTech International, New York, N.Y.; bUniversity of Pittsburgh Medical Center, Pittsburgh, Pa., cRenal Research Institute, New York, N.Y., USA, and dOspedale San Bortolo, Vicenza, Italy
Renal replacement therapy in acute renal failure is currently focused on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle molecular weight toxins, consisting of small proteins, and cytokines involved in the systemic inflammatory response syndrome (SIRS). Conventional high-flux dialyzers are not efficient at removing these molecules, prompting the investigation of sorbents to augment or replace dialysis. Sorbents have been developed to modulate SIRS by targeting cytokines such as IL-1, IL-6, IL-10, IL-18 and TNF, among others. Extensive pre-clinical studies are underway to demonstrate the clinical utility and safety of either adding sorbent hemoadsorption devices to hemodialysis, or the use of such devices alone in SIRS, sepsis, acute renal failure, cardiopulmonary bypass and end-stage renal disease.
James F. Winchester
RenalTech International, LLC
320 East 65th Street, #117
New York, NY 10021 (USA)
Tel. +1 212 717 8644, Fax +1 212 717 8643, E-Mail firstname.lastname@example.org
Number of Figures : 2, Number of Tables : 2, Number of References : 37
Founded 1983; edited by K. Schaefer (1983–1988)
Official Journal of the International Society of Blood Purification and the Vascular Access Society (VAS)
Vol. 21, No. 1, Year 2003 (Cover Date: 2003)
Journal Editor: K.M.L. Leunissen, Maastricht
ISSN: 0253–5068 (print), 1421–9735 (Online)
For additional information: http://www.karger.com/bpu